A Case with Familial Mediterranean Fever which Responds Well to Adalimumab Treatment
Ozgur Ortancil, A. Sanli, Perihan Sapmaz Bulmus, Selda Sarikaya
article (Uluslararası, Hakemli) | Yazar(lar): Ozgur Ortancil, A. Sanli, Perihan Sapmaz Bulmus, Selda Sarikaya | Yıl: 2011 | Dergi/Kurum: TURKISH JOURNAL OF RHEUMATOLOGY | İndeks: WOS.SCI | DOI: 10.5606/tjr.2011.024 | Anahtar Kelimeler: Adalimumab, ankylosing spondylitis, familial Mediterranean fever, tumor necrosis fac
Ankylosing spondylitis (AS) may accompany Familial Mediterranean fever (FMF). In this article, we present a 48-year-old male FMF case with accompanying AS who was successfully treated with a tumor necrosis factor-alpha (TNF-alpha) inhibitor (adalimumab). Colchicine and other disease modifying antirheumatic drug (sulfasalazine and leflunomide) treatments had been given before the initiation of the TNF-alpha inhibitor, but FMF attacks could not be adequately controlled by these treatments. When adalimumab was coadministered with colchicine, the disease activity of AS was improved and the frequency and the severity of the FMF attacks were reduced during the one-year follow-up. We conclude that TNF-alpha blockers may be a therapeutic option when conventional treatment is ineffective in patients with FMF.